Abstract Rational use of phosphodiesterase inhibitors represents an ongoing controversy in contemporary pharmacotherapy for heart failure. In randomized clinical trials, phosphodiesterase inhibitors increased cardiac output at the expense of worsening the rates of sudden cardiac death and cardiovascular mortality. Preliminary findings from ongoing clinical and preclinical investigations of phos...

Phosphodiesterase 4 (PDE4) has been established as a promising target in asthma andchronic obstructive pulmonary disease. PDE4B subtype selective inhibitors are known toreduce the dose limiting adverse effect associated with non-selective PDE4B inhibitors. Thismakes the development of PDE4B subtype selective inhibitors a desirable research goal. Toachieve this goal, ligand based pharmacophore m...

PURPOSE Experimental evidence suggests that phosphodiesterase type 5 inhibitors may suppress tumor growth, postpone metastasis and prolong survival, but clinical data are lacking. We studied the effect of phosphodiesterase type 5 inhibitors on biochemical recurrence after radical prostatectomy for prostate cancer. MATERIALS AND METHODS The study was comprised of 4,752 consecutive patients wit...

Advancements in phosphodiesterase (PDE)-targeted therapies have shown promise in recent years for treating patients with a variety of autoimmune diseases. This review summarizes the development of PDE4 inhibitors and the associated literature with a focus on treatments for autoimmune diseases. After the initial investigations of the prototypic PDE inhibitor, rolipram, more selective inhibitors ...

Erectile dysfunction after radical prostatectomy is a major complication affecting postoperative quality of life. For early recovery from postoperative erectile dysfunction, attention has focused on penile rehabilitation using vacuum devices, prostaglandin E1 injection into the corpus cavernosum of the penis or transurethral administration, and oral drugs such as phosphodiesterase type 5 inhibi...

In this article, I reflect on a 40-year career in drug discovery at Bristol Myers Squibb that encompassed the cardiovascular, central nervous system and antiviral therapeutic areas. share scientific observations made design optimization of cAMP phosphodiesterase inhibitors, prostacyclin partial agonists, maxi-K ion channel openers, influenza respiratory syncytial virus hepatitis C NS3/4A protea...

weight-gain and potency enhancing drugs are the most popular herbal products in iran which are easily available via the internet and through illegal markets. the content of some of these popularly purchased products were investigated for the presence of illegal substance like phosphodiesterase inhibitors (pdh-5) and corticosteroids by hplc method. for this study, ten samples of both kind of her...

Little is known about of the comparative cardiac lusitropic and coronary vasoactive effects of type III phosphodiesterase inhibitors independent of their systemic circulatory effects. We hypothesized that phosphodiesterase inhibitors have dissimilar concentration-dependent effects on cardiac function and metabolism and that their coronary vasodilatory effects are solely dependent on flow autore...

Alzheimer’s disease is a memory-related neurodegenerative condition leading to cognitive impairment. Cholinergic deficit, together with other underlying mechanisms, leads the onset and progression of disease. Consequently, acetylcholinesterase inhibitors are used for symptomatic treatment dementia, even if limited efficacy observed. More recently, some specific phosphodiesterase isoforms emerge...